Acetylcholine Mediates the Estrogen-Induced Increase in NMDA Receptor Binding in CA1 of the Hippocampus and the Associated Improvement in Working Memory

Jill M. Daniel and Gary P. Dohanich

Department of Psychology, Tulane University, New Orleans, Louisiana 70118

Elevated levels of circulating estrogen in female rats result in increased spine and synapse density and parallel increases in NMDA receptor binding in area CA1 of the hippocampus. Estrogen also influences cholinergic neurochemistry in the basal forebrain and hippocampus. The objectives of the present study were to determine the role of acetylcholine in the estrogen-induced increase in NMDA receptor binding in CA1 of the hippocampus and to investigate the relationship between increased NMDA receptor binding in CA1 and performance on a task of working memory. In the current experiments, elevating endogenous levels of acetylcholine in ovariectomized rats by 3 d of continuous administration of physostigmine, an acetylcholinesterase inhibitor, increased NMDA receptor binding in CA1 as measured by quantitative autoradiography. This increase was comparable with the increase in NMDA receptor binding induced by injections of estradiol benzoate 72 and 48 hr before death. Additionally, the administration of 5,11-dihydro-8-chloro-11-[2,2-dimethyl-1-oxopentyl]ethylamino]propyl]-1-piperidiny]acetyl]-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one (BIBN 99), an M2 receptor antagonist, blocked the ability of both estrogen and physostigmine to increase NMDA receptor binding. The regimen of estradiol replacement that was demonstrated to increase NMDA receptor binding in CA1 of ovariectomized rats also improved arm-choice accuracy in a working memory task in an eight-arm radial maze. The estrogen-induced improvement in working memory performance was blocked by BIBN 99, which also blocked the increase in NMDA receptor binding. These results indicate that acetylcholine acts at M2 muscarinic receptors to mediate the estrogen-induced increase in NMDA receptor binding in CA1 of the hippocampus as well as the associated improvement in working memory.

Key words: estrogen; acetylcholine; hippocampus; learning; memory; NMDA receptors; M2 muscarinic receptors

The ovarian hormone estrogen affects performance on various measures of learning and memory in mammals, although the mechanisms underlying these effects are unknown. Estrogen induces morphological changes and modulates excitatory and inhibitory neurotransmission in the hippocampus, an area of the brain implicated in learning and memory. For example, spine and synapse density on CA1 pyramidal cells is positively correlated with estrogen levels, as indicated by experiments in which endogenous estrogen was manipulated (Gould et al., 1990) and in which estrogen levels varied across the rat estrous cycle (Woolley et al., 1997). Interestingly, estradiol-induced increases in spine density in CA1 correlated positively to increased NMDA but not AMPA receptor binding as well as to increased sensitivity of CA1 pyramidal cells to AMPA receptor-mediated synaptic input (Woolley et al., 1997). In addition to increasing the density of dendritic spines on pyramidal cells in vitro (Murphy and Segal, 1996), estradiol decreased levels of glutamic acid decarboxylase (GAD), the GABA-synthesizing enzyme, and decreased GABAergic miniature IPSCs (Murphy et al., 1998), indicating that estradiol-induced spine formation results from a disinhibition of hippocampal pyramidal cells that occurs after reduction of GABAergic inhibition.

Transection of the fimbria/fornix, which contains the majority of the subcortical afferents to the hippocampus, prevented an estradiol-induced increase in dendritic spine density on CA1 pyramidal cells (Leranth et al., 2000). The fimbria/fornix contains the cholinergic input to the hippocampus from the medial septal/diagonal band complex (Paxinos, 1995). Estrogen facilitates cholinergic neurotransmission in the septal–hippocampal pathway as evidenced by its ability to increase activity and mRNA of choline acetyltransferase (Luine, 1985; Gibbs and Pfaff, 1992; Gibbs et al., 1994), high-affinity choline uptake (O’Malley et al., 1987; Singh et al., 1994), and acetylcholine release (Gibbs et al., 1997). Acetylcholine regulates hippocampal GABA release via action at the M2 subtype of the muscarinic receptor located on axon terminals of GABAergic basket and chandelier cells, interneurons that provide powerful input to pyramidal cells (Freund and Gulyas, 1997; Hajos et al., 1998). Thus, these presynaptically located M2 receptors provide a mechanism by which the estrogen-induced elevation of acetylcholine could reduce hippocampal GABA release resulting in disinhibition of CA1 pyramidal cells.

Although estrogen affects learning and memory performance, to date there are no published reports that associate the estradiol-induced changes in spine density and NMDA receptor binding in CA1 to improvements in performance on tasks that measure learning and memory. Estrogen impairs or has no effect on tasks dependent on spatial reference memory, defined as memory for information consistent across trials (Galea et al., 1995; Berry et
The physostigmine implants maintained concentration (10% ethanol, 40% propylene glycol, and 50% distilled water) or sham and preincubated in slide mailers containing 10 ml of 50 mM Tris-acetate buffer (Sigma), pH 7.4, for 45 min at room temperature to remove air. Six sections per brain were incubated in slide mailers containing 200 nM [3H]glutamate plus 1 mM NMDA (Sigma). The physostigmine implants maintained constant delivery rates of physostigmine at 0.06 mg·kg⁻¹·hr⁻¹, or (3) physostigmine at 0.06 mg·kg⁻¹·hr⁻¹. Treatments. Three days after ovariectomy, rats were implanted subcutaneously with osmotic mini-pumps (Alza, Palo Alto, CA) containing physostigmine hemisulfate (Sigma, St. Louis, MO) in vehicle solution (10% ethanol, 40% propylene glycol, and 50% distilled water) or sham pumps while under anesthesia induced by injection of ketamine (100 mg/kg, i.p.; Bristol Laboratories, Syracuse, NY) and xylazine (7 mg/kg, i.p.; Miles Laboratories, Shawnee, KS). Animals were randomly assigned to one of the following groups (n = 9): (1) control, (2) physostigmine at 0.0075 mg·kg⁻¹·hr⁻¹, or (3) physostigmine at 0.06 mg·kg⁻¹·hr⁻¹. Treatments. Thirty days after ovariectomy, animals assigned to the estrogen group were injected intramuscularly with 10 µg (total dose) of estradiol benzoate (Sigma) in 0.1 ml of cottonseed oil vehicle (Woolley et al., 1997). Other groups were implanted with sham pumps. Forty-eight hours after the second estradiol or oil vehicle injection, animals were killed by decapitation. Brains were rapidly removed, frozen on powdered dry ice, and stored at −70°C until sectioning. Receptor autoradiography. Frozen coronal sections, 20 µm thick, were cut on a microtome cryostat, thaw-mounted on gelatinized slides, and stored at −70°C. Twelve consecutive sections were taken through the dorsal hippocampus of each brain, beginning at 2.56 mm posterior to bregma and extending to 2.80 mm posterior to bregma ( Paxinos and Watson, 1998). NMDA receptor binding was determined according to Weiland (1992a). Slide-mounted sections were thawed, dried completely, and preincubated in slide mailers containing 10 ml of 50 mM Tris-acetate buffer (Sigma), pH 7.4, for 45 min at room temperature to remove endogenous ligand. Sections were dried for 10 min under a stream of cool air. Six sections per brain were incubated in slide mailers containing 200 nM [3H]glutamate (51.90 Ci/mmol; NEN, Boston, MA) in Tris-acetate buffer, and six alternate sections per brain were incubated in Tris-acetate buffer containing 200 nM [3H]glutamate plus 1 mM NMDA (Sigma). After incubation, sections were rinsed four times for 5 sec each in ice-cold Tris-acetate buffer and dried rapidly. Sections were placed in contact with tritium-sensitive film (Hyperfilm; Amersham, Uppsala, Sweden) for 30 d with 3H-labeled plastic standards (Microscales; Amersham) that measured relative optical density. The experimenter was blind to treatment conditions during imaging procedures. Measurements were taken for the entire CA1 region of the dorsal hippocampus ( Weiland, 1992a; Cyr et al., 2000), because estrogen treatment increases NMDA receptor binding in both the stratum radiatum and stratum oriens of CA1 ( Woolley et al., 1997). Optical density was converted to concentration of radioligand (picomoles per milligram of protein) on the basis of a standard curve generated from ['H]-labeled plastic standards. To determine NMDA receptor binding, ['H]glutamate binding that remained in the presence of NMDA was subtracted from total ['H]glutamate binding. Previous work in this laboratory revealed an asymmetric distribution of hippocampal muscarinic receptors (Woolf et al., 1997). Therefore, to determine whether a similar asymmetry in the distribution of NMDA receptors was present, means were calculated for each hemisphere of each animal separately.

**Materials and Methods**

**Experiment 1**

**Subjects.** Twenty-seven Long–Evans female rats, ~60 d of age, were purchased from Harlan Sprague Dawley (Indianapolis, IN). Animal care was in accordance with guidelines set by the National Institutes of Health Guide for the Care and Use of Laboratory Animals (1996). Rats were housed individually in a temperature-controlled vivarium under a 12 h light/dark cycle (lights on at 7:00 A.M.). At 65 d of age, all rats were ovariectomized while under anesthesia induced by injection of ketamine (100 mg/kg, i.p.; Bristol Laboratories, Syracuse, NY) and xylazine (7 mg/kg, i.p.; Miles Laboratories, Shawnee, KS). Animals were randomly assigned to one of the following groups (n = 9): (1) control, (2) physostigmine at 0.0075 mg·kg⁻¹·hr⁻¹, or (3) physostigmine at 0.06 mg·kg⁻¹·hr⁻¹.

**Treatments.** Three days after ovariectomy, rats were implanted subcutaneously with osmotic mini-pumps (Alza, Palo Alto, CA) containing physostigmine hemisulfate (Sigma, St. Louis, MO) in vehicle solution (10% ethanol, 40% propylene glycol, and 50% distilled water) or sham and preincubated in slide mailers containing 10 ml of 50 mM Tris-acetate buffer (Sigma), pH 7.4, for 45 min at room temperature to remove air. Six sections per brain were incubated in slide mailers containing 200 nM [3H]glutamate plus 1 mM NMDA (Sigma). The physostigmine implants maintained constant delivery rates of physostigmine at 0.06 mg·kg⁻¹·hr⁻¹, or (3) physostigmine at 0.06 mg·kg⁻¹·hr⁻¹. Treatments. Thirty days after ovariectomy, animals assigned to the estrogen group were injected intramuscularly with 10 µg (total dose) of estradiol benzoate (Sigma) in 0.1 ml of cottonseed oil vehicle (Woolley et al., 1997). Other groups were implanted with sham pumps. Forty-eight hours after the second estradiol or oil vehicle injection, animals were killed by decapitation. Brains were rapidly removed, frozen on powdered dry ice, and stored at −70°C until sectioning. NMDA receptor binding in area CA1 of the hippocampus was determined by quantitative receptor autoradiography as described in Experiment 1.

**Summary.** The schedule of treatment procedures for each group (control, estrogen, physostigmine, and physostigmine + BBIB 99) is summarized in Table 1.

**Experiment 2**

**Subjects.** Forty Long–Evans female rats were obtained at ~60 d of age and ovariectomized at 65 d of age. Housing conditions and surgical procedures were as described in Experiment 1. Animals were assigned to one of the following treatment groups (n = 10): (1) control, (2) estrogen, (3) physostigmine, or (4) physostigmine + BBIB 99.

**Treatments.** Three days after ovariectomy, rats assigned to the physostigmine and the physostigmine + BBIB 99 groups were implanted subcutaneously with osmotic mini-pumps that maintained constant delivery rates of physostigmine at 0.06 mg·kg⁻¹·hr⁻¹, the dose demonstrated in Experiment 1 to increase NMDA receptor binding in CA1. Animals in the other two groups were implanted with sham pumps. Twenty-seven Long–Evans female rats were obtained at ~60 d of age and ovariectomized at 65 d of age. Housing conditions and surgical procedures were as described in Experiment 1. Animals were assigned to one of the following treatment groups (n = 9): (1) control, (2) estrogen, (3) physostigmine, or (4) physostigmine + BBIB 99.

**Treatments.** Thirty days after ovariectomy, animals assigned to the estrogen group were injected intramuscularly with 10 µg (total dose) of estradiol benzoate (Sigma) in 0.1 ml of cottonseed oil vehicle (Woolley et al., 1997). Other groups were implanted with sham pumps. Forty-eight hours after the second estradiol or oil vehicle injection, animals were killed by decapitation. Brains were rapidly removed, frozen on powdered dry ice, and stored at −70°C until sectioning. NMDA receptor binding in area CA1 of the hippocampus was determined by quantitative receptor autoradiography as described in Experiment 1.

**Summary.** The schedule of treatment procedures for each group (control, estrogen, physostigmine, and physostigmine + BBIB 99) is summarized in Table 1.

**Experiment 3**

The following experiment was completed and then replicated with a separate set of animals. Data were combined for analyses.

**Subjects.** Forty Long–Evans female rats were purchased at ~60 d of age. At 70 d of age, all rats were placed on diets to maintain body weight at 80–90% of weights at weaning alone. Forty-eight hours after the second estradiol or oil vehicle injection, animals were killed by decapitation. Brains were rapidly removed, frozen on powdered dry ice, and stored at −70°C until sectioning. NMDA receptor binding in area CA1 of the hippocampus was determined by quantitative receptor autoradiography as described in Experiment 1.

**Training procedures.** Females were trained to obtain food rewards (Kellogg’s Froot Loops) from the arms of an elevated eight-arm radial maze obtained commercially from Lafayette Instruments (Lafayette, IN). The maze consisted of black metal floors and clear Plexiglas walls. The eight arms (10 cm wide × 70 cm long × 20 cm high) were separated from an octagonal center compartment (33 cm across) by guillotine doors that could be opened or closed silently by mechanical relay. The room in which the maze was located contained fixed extramaze cues. To begin each training trial, the rat was placed in the center compartment of the maze with the doors of the arms closed. All doors then were opened, and the rat was allowed to enter any of the eight arms. The experimenter, who was seated in the room at a fixed location ~5 feet from the maze, recorded arm choices. An arm choice was scored if the rat traveled halfway down the length of an arm. An error was scored if a rat reentered an arm visited previously. The rat was allowed to choose arms in any order until all arms were visited or until 5 min had elapsed. Beginning on the sixth training trial, the animal was removed from the maze after it had made four correct arm choices and placed in a holding cage for a period of 10 min. It then was returned to the center compartment of the maze with all arms opened and allowed to choose arms in any order until all arms were visited or until a total of 6 min had elapsed. This training procedure was used to acclimate the animal to the test trial procedure, in which a longer delay was instituted between the fourth and fifth arm
Table 1. The schedule of treatment procedures for Experiment 2

<table>
<thead>
<tr>
<th>Day</th>
<th>Procedure</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>Sham pumps (C, E) or pumps delivering continuous physostigmine (PH, PH + B) implanted</td>
</tr>
<tr>
<td>4</td>
<td>BIBN (PH + B) or vehicle (C, E, PH) injections every 4 hr</td>
</tr>
<tr>
<td>5</td>
<td>EB (E) or oil injection (C, PH, PH + B)</td>
</tr>
<tr>
<td>6</td>
<td>Killed</td>
</tr>
</tbody>
</table>

C, Control; E, estrogen; EB, estradiol benzoate; PH, physostigmine; PH + B, physoestigmine + BIBN 99.

chooses. Accuracy was scored by two measures, the number of correct choices until the first error and the number of correct choices in the first eight visits.

Rats were trained on the task for one trial per day for 18 d, at which time all females had reached a criterion of 80% correct averaged over three consecutive training trials. At the point that animals were ovariectomized and randomly assigned to one of the following groups (n = 9): (1) control, (2) estrogen, (3) estrogen + BIBN 99, or (4) BIBN 99. After ovariectomy, animals were trained on the maze every other day until testing to maintain performance levels.

Treatments. On days 3 and 4 after ovariectomy, animals assigned to the estrogen and the estrogen + BIBN 99 groups were injected intramuscularly with 10 μg of estradiol benzoate in 0.1 ml of cottonseed oil vehicle. Animals in the other two groups were injected with 0.1 ml of vehicle alone. At the time of the first injection of estradiol or oil, animals assigned to estrogen + BIBN 99 and to BIBN 99 were also injected with BIBN 99 (0.05 mg/kg, s.c.) delivered in 4.2% aqueous d-mannitol solution. Animals in the other two groups were injected with vehicle alone. Additional injections of BIBN 99 or vehicle were given every 4 hr until testing. Approximately 48 hr after the second estradiol or oil injection, animals were tested on the eight-arm radial maze.

Testing procedures. The test trial was conducted in a manner identical to that of the training trials with one exception. After the animal made four correct arm choices, it was removed from the maze and placed in a holding cage for 3 hr. It then was returned to the maze to complete the test trial.

Summary. The schedule of training, treatment, and testing procedures for each group (control, estrogen, estrogen + BIBN 99, and BIBN 99) is summarized in Table 2.

Experiment 4

Immediately after testing on the radial maze, rats from the first replication of Experiment 3 were killed (n = 9), and NMDA receptor binding in area CA1 of the dorsal hippocampus was determined by quantitative receptor autoradiography as described in Experiment 1.

RESULTS

Experiment 1

The goal of the first experiment was to determine whether elevating endogenous levels of acetylcholine in ovariectomized rats via continuous administration of physoestigmine, an acetylcholinesterase inhibitor, would increase NMDA receptor binding in CA1 of the hippocampus. Figures 1 and 2 illustrate that ovariectomized rats receiving 3 d of treatment with physoestigmine at 0.06 mg·kg⁻¹·hr⁻¹, a dose demonstrated to cause near-maximal inhibition of cortical acetylcholinesterase activity (Mandel et al., 1989), displayed increased NMDA receptor binding in CA1 of the hippocampus compared with ovariectomized controls. To determine the effect of treatment as well as to determine whether the effect of treatment varied across the hemisphere, data collected from autoradiograms were analyzed by two-way ANOVA (treatment × hemisphere). A significant main effect of treatment was revealed (F(2,44) = 3.246; p < 0.05). Post hoc comparisons indicated that animals that received physoestigmine at 0.06 mg·kg⁻¹·hr⁻¹, but not those that received 0.0075 mg·kg⁻¹·hr⁻¹, displayed significantly higher NMDA receptor binding than did controls (Newman–Keuls, p < 0.05). No effect of hemisphere or interaction of treatment and hemisphere was revealed.

Experiment 2

The results of Experiment 1 demonstrated that elevating endogenous levels of acetylcholine in ovariectomized rats via continuous administration of physoestigmine for 3 d increased NMDA receptor binding in CA1 of the hippocampus. The first objective of Experiment 2 was to compare the effects of physoestigmine and estrogen on NMDA receptor binding. The second objective of Experiment 2 was to determine whether acetylcholine acts at M2 muscarinic receptors to increase NMDA binding in CA1. Specifically, we determined whether systemic administration of an M2 muscarinic receptor antagonist would block the physoestigmine-induced increase in NMDA receptor binding. The M2 muscarinic antagonist 5,11-dihydro-8-chloro-11-[(4-[3-{[(2,2-dimethyl-1-oxopentyl)ethylamino]propyl}]-1-piperidinyl)acetyl]-6H-pyrido[2,3-b] [1,4] benzodiazepin-6-one (BIBN 99), was used because it exhibits a high affinity for rat cardiac M2 sites (IC₅₀, 30 nm) and a low affinity for rat cortical M1 (IC₅₀, 676 nm) and rat submandibular M3 (IC₅₀, 690 nm) (Dooods et al., 1993) sites. Figure 3 illustrates that ovariectomized rats treated with either estrogen or physoestigmine alone exhibited a significant increase in NMDA receptor binding compared with controls.

Table 2. The schedule of training, treatment, and test procedures for Experiment 3

<table>
<thead>
<tr>
<th>Day</th>
<th>Maze training begins</th>
<th>Procedure</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Ovariectomy</td>
<td>EB (E, E + B) or oil (C, B) injection</td>
</tr>
<tr>
<td>18</td>
<td></td>
<td>BIBN (E, E + B, B) or vehicle (C, E) injections every 4 hr</td>
</tr>
<tr>
<td>21</td>
<td></td>
<td>EB or oil injection</td>
</tr>
<tr>
<td>22</td>
<td></td>
<td>BIBN or vehicle injections continue</td>
</tr>
<tr>
<td>23</td>
<td></td>
<td>EB or oil injection</td>
</tr>
<tr>
<td>24</td>
<td></td>
<td>BIBN or vehicle injections continue</td>
</tr>
</tbody>
</table>

B, BIBN 99; C, control; E, estrogen; E + B, estrogen + BIBN 99; EB, estradiol benzoate.
binding in CA1 of the hippocampus compared with ovariec-
tomized controls. Animals that were treated with the M2 musca-
ринic receptor antagonist BIBN 99 along with physostigmine did
not exhibit this increase in NMDA receptor binding. Binding
values expressed in picomoles per milligram of protein were
analyzed by two-way ANOVA (treatment × hemisphere). There
was a significant main effect of treatment ($F_{(3,54)} = 3.826; p <
0.02$). Post hoc comparisons indicated that animals that received
either estrogen or physostigmine alone, but not those that re-
ceived physostigmine + BIBN 99, displayed significantly higher
NMDA receptor binding than did controls (Newman–Keuls, $p <
0.05$). No effect of hemisphere or interaction of hemisphere with
treatment was found.

**Experiment 3**

The first objective of Experiment 3 was to determine whether the
regimen of estradiol replacement demonstrated previously to
induce formation of new dendritic spines (Gould et al., 1990;
Woolley et al., 1997) and to increase NMDA receptor binding in
CA1 (see Results of Experiment 2) (see also Woolley et al., 1997)
would enhance performance on a task of working memory. The
second objective was to determine whether an estradiol-induced
enhancement of working memory was mediated by the action of
acetylcholine on M2 receptors. Specifically, the effects of systemic
injections of estradiol given to ovariectomized rats 72 and 48 hr
before testing on an eight-arm radial maze were assessed, and it
was determined whether chronic administration of BIBN 99, an
M2 antagonist, would counteract the effects of estradiol on work-
ning memory performance. Figure 4A illustrates that ovariec-
tomized rats treated with two injections of estradiol 72 and 48 hr
before testing displayed enhanced working memory performance
on the eight-arm radial maze compared with estradiol-treated
animals also treated with BIBN 99, animals treated with BIBN 99
alone, and ovariectomized controls. Choice accuracy data col-
clected on the test trial were analyzed by a one-way ANOVA (treatment) followed by post hoc comparisons. There was a sig-
nificant main effect of treatment ($F_{(3,54)} = 7.752; p < 0.01$), for
the number of correct choices until the first error (Fig. 4A).
Animals treated with estradiol alone made significantly more
correct arm choices until the first error than did animals treated
with estradiol + BIBN 99, animals treated with BIBN 99 alone,
or control animals (Newman–Keuls, $p < 0.05$). There was also a
significant main effect of treatment ($F_{(3,64)} = 2.910; p < 0.01$), for
the number correct in the first eight visits (Fig. 4B). Animals
-treated with estradiol alone made significantly more correct arm
choices in the first eight visits than did animals treated with BIBN
99 alone (Newman–Keuls, $p < 0.05$). However, no other signifi-
cant group differences were revealed for this measure of arm-
choice accuracy.

**Experiment 4**

In Experiment 4, NMDA receptor binding was measured in
brains taken from rats used in behavior testing in Experiment 3.
The objective of Experiment 4 was to determine whether acetyl-
choline mediates the estradiol-induced increase in NMDA recep-
tor binding by acting at M2 receptors. Therefore, it was deter-
mined whether administration of BIBN 99, the M2 antagonist,
would block the estradiol-induced increase in NMDA receptor
binding in CA1 of the hippocampus. Additionally, it was deter-

![Figure 1. Representative autoradiograms of $[^{3}H]$glutamate binding in
the dorsal hippocampus in brains taken from ovariectomized rats receiv-
ing control treatment (A), 3 d of chronic treatment of physostigmine at
0.0075 mg · kg$^{-1}$ · hr$^{-1}$ (B), or 3 d of chronic treatment of physostigmine
at 0.06 mg · kg$^{-1}$ · hr$^{-1}$ (C). Left panels illustrate total $[^{3}H]$glutamate
binding, and right panels illustrate $[^{3}H]$glutamate binding that remained
in the presence of NMDA. NMDA binding was taken to be the amount of
total $[^{3}H]$glutamate binding displaced by NMDA (difference between left
and right panels). Arrows indicate the area in which measurements were
taken.

![Figure 2. Effect of the acetylcholinesterase inhibitor physostigmine on
NMDA-displaceable $[^{3}H]$glutamate binding in CA1 of the dorsal hip-
campus of ovariectomized rats. Osmotic minipumps delivered phy-
so stigmine ($PH$) for 3 d at constant rates of 0.0075 or 0.06
mg · kg$^{-1}$ · hr$^{-1}$. After death, NMDA receptor binding was determined
via in vitro quantitative receptor autoradiography. Values reported are total
$[^{3}H]$glutamate binding minus $[^{3}H]$glutamate binding in the presence
of NMDA (in pmol/mg protein ± SEM). Data were collected from 12
consecutive sections of the dorsal hippocampus between 2.56 and 2.80 mm
posterior to bregma. $^{*}p < 0.05$ vs control (C); Newman–Keuls.

4 A B C PH 0.0075 mg/kg/hr PH 0.06 mg/kg/hr NMDA Binding (pmol/mg protein) 0.0 0.1 0.2 0.3 0.4 0.5 0.6 C PH 0.0075 PH 0.06 mg/kg/hr mg/kg/hr
DISCUSSION

The results of the present experiments indicate that acetylcholine, acting at M2 muscarinic receptors, plays a role in the estradiol-induced increase in NMDA receptor binding in CA1 of the dorsal hippocampus as well as in the associated enhancement of performance on a working memory task. In Experiment 1, elevating endogenous levels of acetylcholine in ovariectomized rats by continuous administration of physostigmine, an acetylcholinesterase inhibitor, increased NMDA receptor binding in CA1. In Experiment 2, it was further shown that the increase in NMDA receptor binding in CA1 induced by physostigmine was comparable with the increase induced by estrogen. Additionally, the administration of BIBN 99, an M2 muscarinic receptor antagonist, prevented the increase in NMDA receptor binding induced by physostigmine. In Experiment 3, the regimen of estradiol replacement shown to increase NMDA receptor binding in CA1 also enhanced working memory performance as assessed in an eight-arm radial maze. In addition, this estradiol-induced enhancement in performance was blocked by administration of BIBN 99. Finally, in Experiment 4, estradiol treatment increased NMDA receptor binding in CA1 in brains taken from animals immediately after maze testing in Experiment 3, an increase that was prevented by systemic administration of BIBN 99.

The present results demonstrate that the ability of estrogen to effect change in NMDA receptor binding in CA1 is related to its ability to alter cholinergic neurochemistry. In a previous report, the muscarinic receptor antagonist scopolamine failed to block the estradiol-induced increase in spine density in ovariectomized rats (Woolley and McEwen, 1994). However, in that experiment scopolamine was administered every 12 hr. Because scopolamine has a half-life of <30 min in rats (Lyeth et al., 1992), it may have been unable to block muscarinic receptors during a significant portion of the period of estrogen exposure. In the present study, continuous release of physostigmine mimicked the effect of estradiol on levels of NMDA receptor binding in CA1, an effect that was demonstrated across two experiments.

The results of the current experiments indicate that acetylcholine acts at the M2 subtype of the muscarinic receptor to affect levels of NMDA receptor binding in CA1. Although the specific mechanisms by which increased levels of acetylcholine act at M2 muscarinic receptors to increase NMDA receptor binding cannot be determined from the results of the present experiments, there are interesting possibilities. Cholinergic neurons in the medial septal/diagonal band complex contain estrogen receptors (Shugh-
The resultant inhibition of hippocampal GABA interneurons would contribute to disinhibition of the pyramidal cells. Blocking the M2 muscarinic receptors in the medial septal region and diagonal band complex could, at least partly, be responsible for the ability of BIBN 99 to counteract the effects of physostigmine and estradiol on CA1 NMDA receptor binding. Clearly, further work is needed to identify the specific mechanisms by which acetylcholine acts at the M2 subtype of the muscarinic receptor to increase NMDA receptor binding in CA1 of the hippocampus. In addition, it is important to note that it is currently unknown whether the mechanism by which estrogen increases CA1 NMDA receptor binding is the same as the mechanism by which estrogen induces parallel increases in CA1 dendritic spine and synapse density (Gould et al., 1990; Woolley et al., 1997). Furthermore, although acetylcholine acts at M2 receptors to increase NMDA receptor binding in CA1, the possible increases in spine and synapse density of CA1 pyramidal cells induced by acetylcholine have not been investigated.

Although the present results indicate that estrogen interacts with the cholinergic system to increase NMDA binding in CA1, estrogen could also act via other mechanisms to influence NMDA receptor binding as well as spine and synapse density. For example, estrogen may act directly on hippocampal GABAergic interneurons to inhibit GABA activity and thus increase the excitatory drive on pyramidal cells, leading to morphological change in CA1 (Murphy et al., 1998). Immunoreactivity for the classical estrogen receptor (ER-α) is expressed in GABAergic interneurons in the rat hippocampus (Weiland et al., 1997). In the dorsal hippocampus, levels of ER-α immunoreactivity were greatest in the dentate gyrus and stratum radiatum of CA1, although these levels were low in comparison with those of other brain regions such as the hypothalamus. Interestingly, in spite of the ability of estradiol to induce changes in GAD mRNA in the pyramidal cell layer of CA1 (Weiland, 1992b), there were few ER-α immunoreactive cells located in that region. However, results of an in situ hybridization study revealed that in addition to ER-α mRNA, the newly cloned estrogen receptor-β (ER-β) mRNA is also expressed in the hippocampus. In recent autoradiographic studies, binding sites for $^{125}$I-estrogen, a ligand with a similar affinity for both ER-α and ER-β, were localized in the pyramidal cells of CA1–CA3, with the highest levels of binding in the ventral portion of CA2 and CA3 (Shughrue et al., 1997; Shughrue and Merchenthaler, 2000). The roles of ER-α and ER-β in the regulation of GABAergic synapses have yet to be determined.

An important finding of the experiments in the present study is that the changes in NMDA receptor binding in CA1 after acute estrogen treatment were associated with an enhancement in working memory performance in an eight-arm radial maze. In addition, the M2 muscarinic receptor antagonist BIBN 99 was able to counteract the estrogen-induced enhancement in working memory performance. In a previous study, no differences in working memory performance during the acquisition of an eight-arm radial maze were found across the estrous cycle (Stackman et al., 1997). Taken together, these results indicate that the increase in spine and synapse density and the associated increase in NMDA receptor binding that occurs as a result of acute estrogen replacement may contribute to improvements in working memory performance in ovariectomized rats. It remains to be determined whether increases in spine and synapse density and NMDA receptor binding in CA1 are associated with improvements in working memory performance that have been demonstrated to occur after a regimen of chronic estrogen replacement (Daniel et al., 1997; Luine et al., 1998; Gibbs, 1999, 2000).

Although not directly related to the objectives of the present

Figure 5. Effects of estrogen, estrogen plus the M2 receptor antagonist BIBN 99, or BIBN 99 alone on NMDA-displaceable $[^{3}H]$glutamate binding in CA1. Ovariectomized rats received one of the following treatments: control treatment (C), two injections of estradiol benzoate (10 μg) delivered 48 and 72 hr before death (E), two injections of estradiol benzoate plus injections of BIBN 99 (0.05 mg/kg, delivered every 4 hr; E + B), or injections of BIBN 99 alone (B). After death, NMDA receptor binding was determined via in vitro quantitative receptor autoradiography. Values reported are total $[^{3}H]$glutamate binding minus $[^{3}H]$glutamate binding in the presence of NMDA (in pmol/mg protein ± SEM). Data were collected from 12 consecutive sections of the dorsal hippocampus between 2.56 and 2.80 mm posterior to bregma ($p < 0.05$ vs C; E + B; Newman–Keuls).
study, these results provide information as to the effect of an M2 muscarinic receptor antagonist on learning and memory performance. In previous studies, administration of BIBN 99 improved performance on a reference memory task in the Morris water maze in aged memory-impaired (Quirion et al., 1995) and traumatic brain-injured rats (Pike and Hamm, 1995). In contrast, on a task of working memory in a T maze, intrahippocampal administration of the putative M2 antagonist gallamine impaired performance (Messer and Miller, 1988). In the present study, there was not a significant difference in working memory performance between ovariectomized rats treated with BIBN 99 and ovariectomized controls. However, ovariectomized rats treated with estrogen significantly outperformed ovariectomized rats treated with BIBN 99 on a working memory task in the radial arm maze.

In conclusion, the results of the present experiments suggest for the first time a mechanism by which elevated levels of estrogen can lead to increased levels of NMDA receptor binding in CA1 of the hippocampus. Specifically, our results indicate that acetylcholine acts at the M2 subtype of the muscarinic receptor to mediate the estradiol-induced increase in NMDA receptor binding. Importantly, these results also demonstrate that the estradiol-induced increase in NMDA receptor binding is associated with enhancement in working memory performance in an eight-arm radial maze.

REFERENCES


Daniel and Dohanich • Estrogen, Acetylcholine, and NMDA Receptor Binding
on the N-methyl-D-aspartate receptor complex in the CA1 region of the hippocampus. Endocrinology 131:662–668.

Weiland NG (1992b) Glutamic acid decarboxylase messenger ribonucleic acid is regulated by estradiol and progesterone in the hippocampus. Endocrinology 131:2697–2702.


